반려동물 백신 시장 - 세계 예측(2026-2032년)

The Companion Animal Vaccine Market is projected to grow by USD 9.54 billion at a CAGR of 8.48% by 2032.

Companion Animal Vaccine Market: Executive Introduction

The companion animal vaccine landscape is being shaped by rising pet ownership, heightened awareness of preventive veterinary care, expanding pet insurance adoption, and greater attention to zoonotic disease prevention. Vaccines for dogs, cats, and other companion animals remain central to routine wellness protocols, supporting protection against rabies, canine distemper, parvovirus, adenovirus, leptospirosis, feline panleukopenia, feline calicivirus, feline herpesvirus, and other infectious threats. Regulatory guidance and veterinary association recommendations continue to distinguish core vaccines, which are broadly recommended based on disease severity and public health relevance, from non-core vaccines, which are selected according to lifestyle, geography, exposure risk, and individual animal health status. Demand is further reinforced by urbanization, increased human-animal bonding, growth in veterinary clinic networks, and improved cold-chain and distribution capabilities. At the same time, the sector faces persistent challenges, including vaccine hesitancy among some pet owners, variable access to veterinary services, compliance gaps in booster schedules, and the need for transparent adverse event monitoring. The industry is therefore moving toward evidence-led immunization strategies that combine clinical efficacy, safety surveillance, owner education, and individualized veterinary decision-making.

Transformative Shifts in the Companion Animal Vaccine Landscape

The companion animal vaccine sector is undergoing structural change as veterinary medicine shifts from reactive treatment toward proactive, preventive care. Clinics are increasingly integrating vaccination with wellness examinations, parasite control, dental care, nutrition counseling, and digital health records, creating more consistent preventive health engagement. Another major transformation is the refinement of vaccination protocols around risk-based medicine. Rather than relying solely on standardized schedules, veterinarians increasingly evaluate lifestyle, travel patterns, boarding exposure, local disease prevalence, age, reproductive status, immune competence, and prior vaccine history. Advances in vaccine technology are also reshaping the landscape, including recombinant platforms, vector-based approaches, improved adjuvant systems, and combination vaccines designed to reduce handling stress and improve compliance. Public health priorities remain a major driver, particularly for rabies vaccination, where companion animal immunization is recognized as a key component of human rabies prevention under One Health strategies. Distribution models are also evolving, with veterinary hospitals, mobile clinics, shelters, animal welfare programs, and digitally enabled appointment ecosystems improving access. These shifts are creating a more data-informed, geographically responsive, and pet-owner-centric vaccine environment.

Cumulative Impact of Artificial Intelligence on Companion Animal Vaccines

Artificial intelligence is beginning to influence companion animal vaccination through clinical decision support, epidemiological monitoring, pharmacovigilance, customer engagement, and operational efficiency. AI-enabled veterinary practice systems can support reminders for booster compliance, identify pets at risk of missed vaccinations, and help clinics segment animals by age, breed, lifestyle, and local disease exposure. In disease surveillance, machine learning can analyze diagnostic records, geospatial signals, shelter intake patterns, laboratory submissions, and public health data to identify emerging infection clusters that may require targeted vaccine awareness. AI can also strengthen adverse event reporting by detecting patterns across large datasets, improving signal identification while supporting regulatory and clinical review. In product development, computational biology and predictive modeling can accelerate antigen selection, immune-response analysis, and formulation screening, although veterinary validation and regulatory evidence remain essential. For manufacturers, distributors, and veterinary service providers, AI can improve cold-chain monitoring, inventory planning, demand synchronization, and appointment scheduling. The cumulative impact is a transition from periodic vaccination transactions toward continuous preventive health management, provided that data privacy, interoperability, clinical oversight, and transparent model governance are maintained.

Key Regional Insights Across Companion Animal Vaccine Adoption

Asia-Pacific is characterized by rapid companion animal adoption, expanding urban middle-class pet spending, and growing demand for modern veterinary services across China, India, Japan, South Korea, Australia, and Southeast Asia. Rabies prevention remains a major public health priority in several countries, while higher-income markets emphasize premium veterinary care, lifestyle-based vaccination, and advanced clinic infrastructure. North America benefits from mature veterinary networks, high awareness of core vaccination protocols, broad availability of diagnostic and preventive care, and strong uptake of digital reminder systems that support compliance. The United States and Canada also maintain established rabies control frameworks, reinforcing the role of companion animal vaccination in public health. Latin America shows strong relevance for rabies vaccination, canine infectious disease prevention, and access expansion through public campaigns, private clinics, and animal welfare initiatives, with Brazil and Mexico serving as important veterinary care hubs. Europe is shaped by regulated veterinary standards, high pet humanization, cross-border pet travel requirements, and emphasis on pharmacovigilance, with companion animal vaccination closely linked to animal welfare and disease prevention policy. The Middle East is seeing increased pet ownership, premium clinic development, and greater focus on preventive veterinary services in urban centers, particularly across Gulf countries where imported pets and expatriate ownership patterns increase the importance of documentation and routine immunization. Africa presents a dual landscape, with growing urban pet care in major cities and continued reliance on rabies vaccination campaigns and One Health programs to reduce zoonotic disease risk, especially where access to routine veterinary services remains uneven.

Key Group Insights Shaping Companion Animal Vaccine Demand

Within ASEAN, companion animal vaccine adoption is influenced by rising pet ownership in urban centers, improving veterinary access, and continuing rabies prevention priorities in several member countries, making education, affordability, and cold-chain reach critical to broader immunization coverage. The GCC reflects a premiumization trend in companion animal care, supported by growing expatriate pet populations, modern veterinary clinics, and increasing demand for preventive health packages, although climate-sensitive logistics and import-dependent supply chains remain important considerations. The European Union provides a highly structured regulatory and animal health environment, where pet travel rules, veterinary pharmacovigilance, welfare policies, and harmonized standards support consistent vaccine quality and compliance. BRICS countries represent diverse but influential demand environments: China and India are expanding veterinary infrastructure and pet health awareness; Brazil has strong relevance in rabies and canine disease prevention; Russia maintains significant companion animal care needs across large geographies; and South Africa supports both private veterinary services and public health-linked vaccination priorities. G7 economies generally demonstrate mature veterinary care systems, high owner awareness, stronger data infrastructure, and established regulatory oversight, encouraging innovation in vaccine quality, safety monitoring, and compliance tools. NATO countries overlap substantially with developed veterinary markets in North America and Europe, where biosecurity awareness, cross-border mobility, and robust healthcare infrastructure reinforce preventive animal health practices, including companion animal vaccination.

Key Country Insights in Companion Animal Vaccine Adoption

The United States remains one of the most advanced companion animal vaccine environments, supported by extensive veterinary service availability, strong core vaccination awareness, state-level rabies requirements, and widespread use of wellness plans and digital reminders. Canada shows similar emphasis on preventive veterinary care, with rabies control requirements varying by province and local risk. Mexico combines private pet healthcare growth with ongoing public health relevance for rabies prevention. Brazil has a large companion animal population and long-standing public vaccination activity, particularly around rabies, while private clinics increasingly support broader canine and feline immunization. The United Kingdom emphasizes evidence-based vaccination protocols, pet travel compliance, and high owner engagement with veterinary preventive care. Germany, France, Italy, and Spain demonstrate strong veterinary infrastructure, high pet ownership, and regulatory alignment with European animal health standards, supporting consistent use of core and risk-based vaccines. Russia presents opportunities linked to companion animal care across major urban areas, though geographic scale can affect distribution consistency. China is experiencing rapid growth in pet healthcare awareness, urban clinic expansion, and demand for premium preventive services. India combines fast-rising pet ownership with major rabies prevention needs, making both public education and veterinary access essential. Japan has an established companion animal healthcare culture, aging pet demographics, and strong preventive care orientation. Australia benefits from high veterinary standards, biosecurity awareness, and strong owner willingness to invest in pet health. South Korea continues to see rapid pet humanization, urban veterinary clinic growth, and increasing interest in structured wellness and vaccination programs.

Actionable Recommendations for Companion Animal Vaccine Leaders

Industry leaders should prioritize evidence-based vaccine education for pet owners, emphasizing the distinction between core and non-core vaccines, the importance of booster compliance, and the role of vaccination in preventing zoonotic disease. Veterinary stakeholders should adopt risk-based protocols that account for geography, lifestyle, age, immune status, travel, boarding exposure, and local disease surveillance, while maintaining alignment with recognized veterinary guidelines and local regulations. Strengthening cold-chain reliability, inventory visibility, and last-mile distribution is essential, particularly in emerging markets and regions with temperature-sensitive logistics. Digital engagement should be expanded through automated reminders, electronic vaccination records, client education portals, and integration with wellness plans to reduce missed vaccinations. Manufacturers and service providers should invest in pharmacovigilance systems that encourage transparent adverse event reporting and support trust in vaccine safety. Partnerships with shelters, animal welfare groups, public health agencies, and mobile veterinary programs can improve access for underserved populations. Innovation efforts should focus on safety, duration of immunity, combination convenience, ease of administration, and clinically validated platform technologies. Leaders should also use AI responsibly to improve surveillance, compliance, and operational efficiency while ensuring data privacy, veterinary oversight, and regulatory alignment.

Research Methodology for Companion Animal Vaccine Insights

This executive summary is built using a secondary research framework focused on verified and data-backed sources, including veterinary association vaccination guidelines, regulatory agency publications, public health references, peer-reviewed veterinary literature, animal health policy documents, and recognized disease surveillance resources. The analysis prioritizes qualitative evidence related to vaccine adoption drivers, infectious disease prevention, regional public health priorities, veterinary infrastructure, regulatory practices, pet ownership trends, and technology-enabled care delivery. Cross-validation is applied by comparing information across clinical guidance, government sources, academic publications, and industry-relevant veterinary health documentation. The methodology excludes market sizing, market estimation, market share analysis, and forecasting to maintain compliance with the stated scope. Regional, group, and country insights are interpreted through factors such as veterinary access, rabies control relevance, companion animal ownership behavior, regulatory maturity, digital health adoption, and preventive care awareness. Artificial intelligence implications are assessed based on documented use cases in clinical decision support, surveillance analytics, pharmacovigilance, logistics, and veterinary practice management, while recognizing the continued need for clinical validation and regulatory oversight.

Conclusion: Advancing Preventive Health Through Companion Animal Vaccines

Companion animal vaccines remain a cornerstone of preventive veterinary medicine and public health protection. The sector is evolving toward more individualized, risk-based, and digitally supported immunization strategies that improve compliance and strengthen disease prevention. Regional dynamics differ significantly: mature markets emphasize protocol optimization, safety monitoring, and owner engagement, while emerging markets focus on access, rabies prevention, veterinary infrastructure, and awareness-building. Artificial intelligence is set to enhance the ecosystem through better compliance tracking, disease surveillance, pharmacovigilance, and operational efficiency, but its use must remain transparent, secure, and veterinarian-led. Success will depend on combining scientific rigor, responsible innovation, accessible distribution, and clear communication with pet owners. Organizations that align vaccination strategies with local disease risk, regulatory expectations, and evolving pet care behaviors will be best positioned to support healthier companion animals and stronger One Health outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Companion Animal Vaccine Market, by Vaccine Type

• 7.1. Introduction
• 7.2. Inactivated
  • 7.2.1. Split Cell
  • 7.2.2. Whole Cell
• 7.3. Live Attenuated
• 7.4. mRNA
• 7.5. Recombinant
• 7.6. Subunit
• 7.7. Toxoid

8. Companion Animal Vaccine Market, by Animal Type

• 8.1. Introduction
• 8.2. Cats
• 8.3. Dogs

9. Companion Animal Vaccine Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Mucosal
  • 9.2.1. Nasal
  • 9.2.2. Oral
• 9.3. Parenteral
  • 9.3.1. Intramuscular
  • 9.3.2. Subcutaneous

10. Companion Animal Vaccine Market, by End User

• 10.1. Introduction
• 10.2. Veterinary Clinics
• 10.3. Veterinary Hospitals
• 10.4. Pet Owners
• 10.5. Animal Shelters
• 10.6. Research Institutions

11. Companion Animal Vaccine Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Online
  • 11.2.1. E Pharmacies
  • 11.2.2. Manufacturer Websites
• 11.3. Pharmacies
• 11.4. Veterinary Clinics
• 11.5. Veterinary Hospitals

12. Companion Animal Vaccine Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Companion Animal Vaccine Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Companion Animal Vaccine Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Bimeda Biologicals Inc
• 16.2. Biogenesis Bago Animal Health S.A.
• 16.3. Biogenesis Bago S.A.
• 16.4. Biovet S.A.
• 16.5. Bioveta, a.s.
• 16.6. Boehringer Ingelheim International GmbH
• 16.7. Ceva Sante Animale
• 16.8. Dechra Pharmaceuticals PLC
• 16.9. Elanco Animal Health Incorporated
• 16.10. Hester Biosciences Limited
• 16.11. Hipra S.A.
• 16.12. Indian Immunologicals Ltd.
• 16.13. Indian Immunologicals Ltd.
• 16.14. Jinyu Bio-technology Co., Ltd.
• 16.15. Kemin Industries, Inc.
• 16.16. Kyoritsu Seiyaku Corporation
• 16.17. Merck & Co., Inc.
• 16.18. Nisseiken Co., Ltd.
• 16.19. Phibro Animal Health Corporation
• 16.20. Qingdao Yebio Biological Engineering Co., Ltd.
• 16.21. Vaxxinova
• 16.22. Vetoquinol S.A.
• 16.23. Virbac S.A.
• 16.24. Zoetis Inc.